Zenex Animal Health unveiled a novel probiotic strain, Bacillus siamensis ZMT02 (BSZMT02), the revolutionary gut health solution for chicken that improves production indices, while allowing farmers to withdraw gut-acting antibiotics and AGPs. The breakthrough discovery of the novel strain was possible through years of research at the Department of Cell, Molecular Biology and Microbiome Therapeutics, Zydus Research Centre (ZRC), India. Globally, for the first time ever, the discovery pathway involved isolation, strategic screening and strain level characterization of beneficial microflora from healthy chicken gastrointestinal tract. Probiotic candidates identified during the study were rigorously evaluated for safety, performance, stability, anti-inflammatory and anti-microbial parameters. The novel strain, BSZMT02, embodies all the necessary characteristics of an ideal probiotic for chicken enabling antibiotic/AGP free farming and will fuel the probiotic products viz, Improval™ BFS and Improval™ MS.
Scientific presentations were made at Le Meridian, Dhaka, Bangladesh amidst of the farming community and poultry professionals by the research lead in support with local partner A.R.Animal Health, Bangladesh. The events were attended by more than 60 eminent stakeholders in the sector involving, layer and breeder farmers, integrators, feed millers’ consultants and veterinary doctors.
“Antimicrobial resistance (AMR) is a global threat and poultry health sector is under tremendous pressure for restriction on critically important antibiotics and AGPs.” said Dr Arun Atrey, MD & CEO, Zenex AH. “Built upon years of innovation, BSZMT02 is unlike anything available before in the
